28108302|t|Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation
28108302|a|Fabry disease is a lysosomal storage disorder with an incidence of 1:1600 for the late-onset IVS4+919G>A cardiac variant mutation in Taiwan. Signs and symptoms of this cardiac variant include left ventricular hypertrophy, mitral insufficiency and/or arrhythmias. The search for biomarkers that might predict the clinical outcomes and guide treatment options is important. We thus investigated relationships between Fabry disease biomarkers (such as globotriaosylceramide (Gb3), globotriaosylsphingosine (lyso-Gb3)/related analogues) and age, gender, enzyme activity, clinical manifestations and severity of the disease in these patients. Urine and plasma biomarkers were analyzed using tandem mass spectrometry. A large cohort of 191 adult and pediatric Fabry patients carrying the IVS4+919G>A mutation was studied. Some patients were members of the same family. Our results show that the plasma lyso-Gb3 level, and urinary analogue levels of lyso-Gb3 at m/z (+16), (+34), and (+50) adjusted for gender and age had a positive association with the left ventricular mass index, and/or the Mainz Severity Score Index. It might thus be of particular interest to monitor children with high levels of these biomarkers, as part of a longitudinal study in order to determine if the excretion profile at a young age is predictive of the outcomes of disease severity in adulthood.
28108302	0	10	Biomarkers	T201	UMLS:C0005516
28108302	27	50	clinical manifestations	T033	UMLS:C0243095
28108302	54	67	Fabry disease	T038	UMLS:C0002986
28108302	95	102	cardiac	T082	UMLS:C1522601
28108302	111	119	mutation	T038	UMLS:C0026882
28108302	120	133	Fabry disease	T038	UMLS:C0002986
28108302	139	165	lysosomal storage disorder	T038	UMLS:C0085078
28108302	213	224	IVS4+919G>A	T017	UMLS:C0678941
28108302	225	232	cardiac	T082	UMLS:C1522601
28108302	241	249	mutation	T038	UMLS:C0026882
28108302	253	259	Taiwan	T082	UMLS:C0039260
28108302	261	279	Signs and symptoms	T033	UMLS:C0037088
28108302	288	295	cardiac	T082	UMLS:C1522601
28108302	312	340	left ventricular hypertrophy	T038	UMLS:C0149721
28108302	342	362	mitral insufficiency	T038	UMLS:C0026266
28108302	370	381	arrhythmias	T033	UMLS:C0003811
28108302	398	408	biomarkers	T201	UMLS:C0005516
28108302	460	469	treatment	T058	UMLS:C0087111
28108302	535	548	Fabry disease	T038	UMLS:C0002986
28108302	549	559	biomarkers	T201	UMLS:C0005516
28108302	569	590	globotriaosylceramide	T103	UMLS:C0061338
28108302	592	595	Gb3	T103	UMLS:C0061338
28108302	598	622	globotriaosylsphingosine	T103	UMLS:C0082711
28108302	624	632	lyso-Gb3	T103	UMLS:C0082711
28108302	642	651	analogues	T103	UMLS:C0243071
28108302	670	685	enzyme activity	T038	UMLS:C0243102
28108302	687	710	clinical manifestations	T033	UMLS:C0243095
28108302	731	738	disease	T038	UMLS:C0012634
28108302	758	763	Urine	T031	UMLS:C0042036
28108302	768	774	plasma	T031	UMLS:C0032105
28108302	775	785	biomarkers	T201	UMLS:C0005516
28108302	791	799	analyzed	T062	UMLS:C0936012
28108302	806	830	tandem mass spectrometry	T062	UMLS:C0599748
28108302	840	846	cohort	T098	UMLS:C0599755
28108302	874	879	Fabry	T038	UMLS:C0002986
28108302	902	913	IVS4+919G>A	T017	UMLS:C0678941
28108302	914	922	mutation	T038	UMLS:C0026882
28108302	927	934	studied	T062	UMLS:C2603343
28108302	1009	1015	plasma	T031	UMLS:C0032105
28108302	1016	1024	lyso-Gb3	T103	UMLS:C0082711
28108302	1044	1052	analogue	T103	UMLS:C0243071
28108302	1063	1071	lyso-Gb3	T103	UMLS:C0082711
28108302	1137	1145	positive	T033	UMLS:C1514241
28108302	1167	1194	left ventricular mass index	T033	UMLS:C0243095
28108302	1266	1274	interest	T038	UMLS:C0543488
28108302	1278	1285	monitor	T058	UMLS:C0150369
28108302	1321	1331	biomarkers	T201	UMLS:C0005516
28108302	1346	1364	longitudinal study	T062	UMLS:C0023981
28108302	1394	1403	excretion	T038	UMLS:C0221102
28108302	1460	1467	disease	T038	UMLS:C0012634